The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ...

BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) ...

Coronavirus vaccine developers could soon be forced to absorb a hit to their reputation. Apparently, government officials are to recommend to an influential healthcare panel that such products are ...

Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...

BioNTech said it is still targeting 2024 revenues of 2.5 billion euros to 3.1 billion euros. Markets are messy—but the right setups can still deliver triple-digit gains. Join Matt Maley live this ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...

Cell therapy developer Autolus has a lead program under FDA review for a type of blood cancer and in clinical development for other indications. As the company looks ahead to a potential product ...